Beigene (NASDAQ:ONC) Releases Quarterly Earnings Results, Misses Expectations By $0.55 EPS

Beigene (NASDAQ:ONC) posted its earnings results on Thursday. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.55), Zacks reports. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. Beigene updated its FY 2025 guidance to EPS.

Beigene Stock Performance

ONC traded up $19.27 during trading on Thursday, hitting $278.27. 996,197 shares of the company traded hands, compared to its average volume of 402,484. The stock has a market capitalization of $27.23 billion, a price-to-earnings ratio of -33.77, a PEG ratio of 7.73 and a beta of 0.63. Beigene has a 1 year low of $126.97 and a 1 year high of $287.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93.

Insider Activity at Beigene

In related news, SVP Chan Henry Lee sold 1,202 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $258.04, for a total transaction of $310,164.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Xiaobin Wu sold 21,267 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $240.07, for a total transaction of $5,105,568.69. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 58,123 shares of company stock valued at $14,081,527. Corporate insiders own 7.43% of the company’s stock.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.